[Therapy of hyperlipidemia].
The identification of patients with monogenetic lipid disorders and a very high risk of premature coronary heart disease is the prerequisit for an intensive cholesterol lowering therapy with the goal to normalize serum cholesterol and prevent early coronary death which seems possible with the new potent drugs.
Keller
C
C
Medizinischen Poliklinik, Klinikums Innenstadt der Ludwig-Maximilians-Universität München, Deutschland.
D000328:Adult; D000368:Aged; D002648:Child; D003131:Combined Modality Therapy; D018752:Diet, Fat-Restricted; D006801:Humans; D006949:Hyperlipidemias / Q000145:classification / Q000235:genetics / Q000628:therapy*; D006938:Hyperlipoproteinemia Type II / Q000145:classification / Q000235:genetics / Q000628:therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D008875:Middle Aged; D010349:Patient Compliance; D012307:Risk Factors
D000960:Hypolipidemic Agents
Therapie von Hyperlipidämien.